Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Mesenchymal Stem Cell Transplantation Clear all
Completed Not applicable Interventional

Autologous Bone Marrow Concentrate in Knee Osteochondral Allograft Transplantation

NCT04739930
View directory record Official record
Conditions
Cartilage Injury
Interventions
Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation, Control group incision
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 17, 2026, 1:57 AM EDT
Not yet recruiting Phase 1 Interventional

Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications

NCT06649864
View directory record Official record
Conditions
Liver Transplant; Complications, Liver Diseases
Interventions
Autologous adipose derived mesenchymal stromal cells (AMSC)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 17, 2026, 1:57 AM EDT
Active, not recruiting Phase 1 Interventional

Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy

NCT05820711
View directory record Official record
Conditions
Head and Neck Cancer, Xerostomia
Interventions
MSC
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 17, 2026, 1:57 AM EDT
Completed Phase 1 Interventional

Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease

NCT02611167
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg), Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
45 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 17, 2026, 1:57 AM EDT
Completed Phase 1 Interventional

A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation

NCT02685098
View directory record Official record
Conditions
Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease, Vascular Disease, Arterial Occlusive Disease, Arteriosclerosis, Atherosclerosis, Cardiovascular Disease, Pathologic Processes, Orthopedic Procedures, Amputation
Interventions
Allogeneic bone marrow derived mesenchymal stem cells
Biological
Lead sponsor
Indiana University
Other
Eligibility
40 Years to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 17, 2026, 1:57 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 17, 2026, 1:57 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD

NCT00927784
View directory record Official record
Conditions
Heart Failure
Interventions
Mesenchymal Precursor cells (RevascorTM), Cryoprotective media alone
Biological · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
San Diego, California • Washington D.C., District of Columbia • Oak Lawn, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 17, 2026, 1:57 AM EDT
Completed Phase 1 Interventional

Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines

NCT02408432
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure
Interventions
Laboratory Biomarker Analysis, Standard of Care, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 17, 2026, 1:57 AM EDT
Active, not recruiting Phase 2 Interventional

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

NCT03478215
View directory record Official record
Conditions
Renal Transplantation, Mesenchymal Stem Cells
Interventions
Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion
Biological · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 17, 2026, 1:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

NCT01392625
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
Autologous hMSCs, Allogeneic hMSCs
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 95 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 17, 2026, 1:57 AM EDT
Completed Phase 1 Interventional

Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant

NCT00361049
View directory record Official record
Conditions
Cancer
Interventions
graft versus host disease prophylaxis/therapy, fluorescence in situ hybridization, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, in vitro-treated bone marrow transplantation, management of therapy complications
Biological · Genetic · Other + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Oct 17, 2026, 1:57 AM EDT
Terminated No phase listed Observational

Properties of Mesenchymal Stem Cells in Lung Transplant

NCT01668576
View directory record Official record
Conditions
Lung Transplantation
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 17, 2026, 1:57 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer

NCT02068794
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Malignant Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Echocardiography, Multigated Acquisition Scan, Biospecimen Collection, Chest Radiography, Single Photon Tomography and Computed Tomography Scan, Computed Tomography, Magnetic Resonance Imaging
Other · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 17, 2026, 1:57 AM EDT
Suspended Phase 1 Interventional

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

NCT02962661
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 17, 2026, 1:57 AM EDT
Completed Phase 1 Interventional

Mesenchymal Stem Cell and Islet Co-transplantation

NCT02384018
View directory record Official record
Conditions
Chronic Pancreatitis, Diabetes
Interventions
autologous mesenchymal stromal cell
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 69 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 17, 2026, 1:57 AM EDT
Recruiting No phase listed Observational

Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)

NCT06752577
View directory record Official record
Conditions
Chronic Kidney Diseases, Kidney Transplant
Interventions
Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 17, 2026, 1:57 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging

NCT01771679
View directory record Official record
Conditions
Chronic Effect of Ultraviolet Radiation on Photoaged Skin, Dermatologic Disorders
Interventions
Allogeneic Mesenchymal Bone Marrow Cells
Biological
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
40 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
2
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 17, 2026, 1:57 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.

NCT07546942
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, Autism Spectral Disorder
Interventions
Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol, Trial combines use of cSVF and MSCs (cryopres) with diet modification and FMT (fecal material Transplant in adult ASD patients, FMT (Fecal Material Tranplantation), Use autologous cSVF + MSCs (cryo) for management of autoimmune component, anti-inflammatory and immune modulation
Procedure · Dietary Supplement · Behavioral + 1 more
Lead sponsor
Black Tie Medical, Inc.
Industry
Eligibility
10 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Hamilton, Montana
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 17, 2026, 1:57 AM EDT
Completed No phase listed Observational

Mobilization of Mesenchymal Stem Cells During Liver Transplantation

NCT02557724
View directory record Official record
Conditions
Liver Failure, Liver Neoplasm
Interventions
blood samples
Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 17, 2026, 1:57 AM EDT
Completed Phase 1 Interventional

Cord Blood Expansion on Mesenchymal Stem Cells

NCT00498316
View directory record Official record
Conditions
Myelodysplastic Syndrome, Leukemia
Interventions
Cord Blood Infusion, Busulfan, Fludarabine, Rituximab, ATG, Cyclophosphamide, Clofarabine, Total Body Irradiation (TBI), Melphalan, Tacrolimus, Mycophenolate Mofetil, G-CSF
Procedure · Drug · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 17, 2026, 1:57 AM EDT
Completed No phase listed Observational

Evaluation of Trinity Evolution in Patients Undergoing Foot and Ankle Fusion

NCT00988338
View directory record Official record
Conditions
Tibiotalar Arthrodesis, Subtalar Arthrodesis, Calcaneocuboid Arthrodesis, Talonavicular Arthrodesis, Double Arthrodesis (i.e. Calcaneocuboid and Talonavicular), Triple Arthrodesis (i.e. Subtalar, Calcaneocuboid, and Talonavicular)
Interventions
Trinity Evolution
Biological
Lead sponsor
Orthofix Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
10
States / cities
Hollywood, Florida • Baltimore, Maryland • Albuquerque, New Mexico + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 17, 2026, 1:57 AM EDT
Completed Phase 1 Interventional

Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation

NCT00705120
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Bone Marrow Cell Transplantation, Irradiation, Total Body, Cyclophosphamide, Cyclosporin, Mesenchymal Stem Cell Transplantation, Busulfan
Other · Radiation · Drug + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2008 · Synced Oct 17, 2026, 1:57 AM EDT
Terminated Phase 1 Interventional

Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease

NCT04328714
View directory record Official record
Conditions
Acute Leukemia, Myelodysplastic Syndromes
Interventions
Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Drug
Lead sponsor
Edwin Horwitz
Other
Eligibility
1 Year and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 17, 2026, 1:57 AM EDT
Completed Early Phase 1 Interventional

Intra-Osseous Co-Transplant of UCB and hMSC

NCT02181478
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Myelofibrosis, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Lymphoid Malignancies, Chronic Myelogenous Leukemia
Interventions
cyclophosphamide, fludarabine phosphate, total-body irradiation, cyclosporine, mycophenolate mofetil, umbilical cord blood transplantation, mesenchymal stem cell transplantation
Drug · Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 17, 2026, 1:57 AM EDT